CJC-1295 NO DAC
CJC-1295 No DAC, also known as Modified GRF(1-29), is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a molecular weight of approximately 3.3 kDa. It is a modified 29-amino-acid GHRH(1-29) analogue with targeted substitutions designed to improve stability and resistance to enzymatic degradation compared with native GRF(1-29). CJC-1295 No DAC is classified as a growth hormone secretagogue and is available in 2mg, 5mg, and 10mg non-DAC forms for research applications.
CJC-1295 NO DAC
Sale!
CJC-1295 No DAC, also known as Modified GRF(1-29), is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a molecular weight of approximately 3.3 kDa. It is a modified 29-amino-acid GHRH(1-29) analogue with targeted substitutions designed to improve stability and resistance to enzymatic degradation compared with native GRF(1-29). CJC-1295 No DAC is classified as a growth hormone secretagogue and is available in 2mg, 5mg, and 10mg non-DAC forms for research applications.
$95.00
Buy more, save more!
-
Save 3%
Buy 3, get $2.50 off each
$95.00Per item: $92.50Total price: $277.50 -
Save 4%
Buy 5, get $3.75 off each
$95.00Per item: $91.25Total price: $456.25 -
Save 8%
Buy 10, get $7.50 off each
$95.00Per item: $87.50Total price: $875.00
$100.00$95.00
99+% PURITY
All peptides are third-party lab tested.
SECURE PAYMENT
Your payments are secure with our private security network.
FREE SHIPPING
for orders over $250
Description
Additional information
Reviews (0)
CJC-1295 No DAC is designed to act on the pituitary GHRH receptor and is studied for its role in growth hormone signalling and GH/IGF-1 axis research. Unlike CJC-1295 DAC, this version does not include the Drug Affinity Complex used for albumin binding, so it is associated with a shorter duration of action and is commonly discussed in research involving more transient or pulsatile GHRH-like signalling.
In research settings, CJC-1295 No DAC may be used to investigate growth hormone release, GHRH receptor activation, peptide stability, and endocrine signalling models. Its modified structure may extend activity compared with native GHRH fragments, but it should not be described as having the same prolonged circulation profile as CJC-1295 DAC.
There are no reviews yet.